To the Editor:

With full interest, we read the article “Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?” by Ruiz-Nodar et al.1 In fact, I commend the authors for conducting this highly interesting piece of research using the newly pioneered HAS-BLED risk score for estimation of bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention. Evidently, the late-breaking innovation of the HAS-BLED bleeding risk score has paved the way for a long-awaited new insight to patients who need long-term oral anticoagulation (OAC) therapy.2 No wonder then that, very shortly after its introduction, its assessment has been recommended in patients before prescribing antithrombotic therapy by both the 2010 European Society of Cardiology and 2011 Canadian Cardiovascular Society guidelines for the management of atrial fibrillation.3,4 The authors concluded that “Most patients with atrial fibrillation undergoing percutaneous coronary intervention/stenting have a high risk for major bleeding (HAS-BLED score ≥3). Even in these patients, OAC improves prognosis in these patients (reduced mortality and major adverse cardiac events) with an increase in major bleeding.”

I am deeply concerned about some methodologic aspects of the current study by Ruiz-Nodar et al. First, the study was conducted by retrospective analysis of patients enrolled during the period from January 2001 to March 2008, well before the first publication of the HAS-BLED bleeding risk score. This makes it very possible that some variables needed for the calculation of the score would be missing from the database at the time of data collection; for instance, liver function and bleeding predisposition. I wonder how labile internormalized ratio, a necessary component of the score, was assessed in all the patients. Second, as already acknowledged by the authors, the adoption of all-cause death, as a primary end point for antithrombotic therapy by both the 2010 European Society of Cardiology and 2011 Canadian Cardiovascular Society guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–2429.


References


Letter by Nammas Regarding Article, "Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score?"
Wail Nammas

Circ Cardiovasc Interv. 2012;5:e88
doi: 10.1161/CIRCINTERVENTIONS.112.974063
Circulation: Cardiovascular Interventions is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-7640. Online ISSN: 1941-7632

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circinterventions.ahajournals.org/content/5/6/e88

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Interventions can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Interventions is online at:
http://circinterventions.ahajournals.org//subscriptions/